At the time, Merck said it planned to start taking orders in July and would deliver the doses in the U.S. this fall, ahead of the start of the RSV season.

Merck MRK stock has declined 4% since it announced second-quarter results on July 29 before market open. While the company’s ...

Called Enflonsia and developed by Merck & Co., the drug is an antibody intended to prevent illness from RSV, which can be particularly severe in young children.

On Thursday, RFK’s Advisory Committee on Immunization Practices (ACIP) voted to recommend clesrovimab, a new RSV antibody shot made by Merck, for infants 8 months and younger who don’t have ...

The CDC expanded RSV vaccine recommendations to include adults aged 50 and above who have underlying health conditions ...

Merck plans to make Enflonsia available for physicians and healthcare administrators to order in July 2025. Shipments will be delivered before the start of the 2025-2026 RSV season.

FDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstraZeneca By Annika Kim Constantino, CNBC • Published June 9, 2025 • Updated on June 9, 2025 at 3:15 pm ...

Merck’s RSV drug approval and a drug manufacturer winds down Mel Evans/AP By Elaine Chen June 10, 2025 National Biotech Reporter ...

With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and infants, Merck & Co. Inc. steps into a ...

Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus, which was in short supply nationwide during the 2023 RSV season due to unprecedented ...